spacer
home > ebr > spring 2018 > beyond the genome
PUBLICATIONS
European Biopharmaceutical Review

Beyond the Genome

The epigenome may hold the key to precision medicine, revealing critically important chemical modifications within DNA that alter the structure, function, and regulation of genes. This exciting and rapidly evolving area brings new perspectives to fundamental biological processes underpinning human disease, development, and ageing. Targeting of precise and powerful epigenetic mechanisms may advance personalised medicine beyond the realms of genomics, bringing opportunities for novel therapeutics and diagnostics that will improve patient outcomes and make efficient use of healthcare resources.

Epigenetic modifications within genomes do not alter the underlying sequence of DNA. Instead, precise chemical changes to DNA or RNA nucleotides and histone proteins alter the regulation and function of genes. Epigenetic modifications are inheritable and can be added or removed in response to specific external factors. Patientís lifestyles (such as smoking and diet), environment, and the stressors that people are exposed to influence the dynamic structure and function of epigenomes, impacting the delicate balance of chemical modifications that are essential to numerous cellular processes.

Informative Diagnostics

Dysregulation of epigenetic pathways can have disastrous consequences; mutations within epigenetic regulators are among the most prevalent across all cancers (1). In addition to cancers, changes within the epigenome are associated with development of a wide range of diseases and health conditions, including neurological and metabolic diseases (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Jason Mellad is the CEO at Cambridge Epigenetix, which aims to change the way medicine is practised by reducing several routine and important diagnostic screening tests to a simple blood draw using the power of 5hmC epigenetic modification. Jason has a BSc in molecular biology and chemistry from Tulane University, US, and was a Marshall Scholar at the University of Cambridge, UK, where he completed a PhD in medicine.
spacer
Dr Jason Mellad
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

HATRIC-based identification of receptors for orphan ligands (small molecules)

HATRIC-LRC (Ligand Receptor Capture) enables now the identification of small molecule targets on the surface of living cells! Even primary cells!
More info >>

White Papers

ConsulTech GmbH

ConsulTech GmbH

ConsulTech is a consulting company founded in 1992. Since then, we have been supporting biotech-nology, pharmaceutical and medical technology companies as well as research institutions with the entire process of setting-up and executing proposals for R&D projects. In projects funded by the European Commission, ConsulTech supports the coordinator by resuming administrative tasks allow-ing coordinators and partners to fully concentrate on the scientific and technical success of the pro-ject. We solve financial and administrative issues, organise meetings, take care of the timely delivery of milestones and reports and much more.
More info >>

 
Industry Events

SMiís 9th Annual Biosimilars & Biobetters Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement